The European start-up iOnctura SA is developing candidate products with immuno-oncologic and direct anti-tumor properties, and has just dosed its first patient in a Phase I study with lead compound IOA-244, which is supported by funding from a €15m ($16.5m) series A round completed earlier this year.
Geneva, Switzerland-based iOnctura was spun out of Merck KGaA in June 2017 to work on compounds licensed from that...








